Disc Financial Statements From 2010 to 2025

IRON Stock   52.83  1.56  3.04%   
Disc Medicine financial statements provide useful quarterly and yearly information to potential Disc Medicine investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Disc Medicine financial statements helps investors assess Disc Medicine's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Disc Medicine's valuation are summarized below:
Market Capitalization
1.8 B
Earnings Share
(3.96)
We have found one hundred twenty available fundamental signals for Disc Medicine, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Disc Medicine's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to grow to about 1.2 B. Also, Enterprise Value is likely to grow to about 879.5 M
Check Disc Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Disc Medicine's main balance sheet or income statement drivers, such as Net Interest Income of 21.8 M, Interest Income of 22.4 M or Depreciation And Amortization of 140.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Ptb Ratio of 3.53 or Days Sales Outstanding of 0.0. Disc financial statements analysis is a perfect complement when working with Disc Medicine Valuation or Volatility modules.
  
Check out the analysis of Disc Medicine Correlation against competitors.
To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.

Disc Medicine Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets281.5 M496.8 M173.9 M
Slightly volatile
Short and Long Term Debt Total31.5 M30 M19 M
Pretty Stable
Other Current Liabilities10.1 M15.2 M7.1 M
Slightly volatile
Total Current Liabilities17.9 M23.3 M6.6 M
Slightly volatile
Property Plant And Equipment Net1.8 M2.3 M798.2 K
Slightly volatile
Accounts Payable9.2 M7.9 M4.7 M
Slightly volatile
Cash184.1 M192.4 M64.6 M
Slightly volatile
Non Current Assets TotalM3.2 M83.8 M
Slightly volatile
Non Currrent Assets Other796.1 K838 K82.7 M
Slightly volatile
Long Term Debt34.2 M32.6 M11.1 M
Slightly volatile
Cash And Short Term Investments249.5 M489.9 M87.2 M
Slightly volatile
Common Stock Shares Outstanding15.3 M29.9 M6.3 M
Slightly volatile
Liabilities And Stockholders Equity281.5 M496.8 M173.9 M
Slightly volatile
Non Current Liabilities Total28.8 M29.9 M15.7 M
Slightly volatile
Other Current Assets3.4 M3.7 M1.3 M
Slightly volatile
Other Stockholder Equity377.2 M741.3 M135.4 M
Slightly volatile
Total Liabilities41.8 M53.2 M21.9 M
Slightly volatile
Net Invested Capital273.1 M471.9 M167.9 M
Slightly volatile
Property Plant And Equipment Gross2.1 M2.7 M1.3 M
Slightly volatile
Short and Long Term Debt8.7 M4.5 M13.2 M
Slightly volatile
Total Current Assets252.9 M493.6 M88.5 M
Slightly volatile
Capital Stock2.9 KK77.2 M
Slightly volatile
Non Current Liabilities Other609.4 K1.2 M453.1 K
Slightly volatile
Net Working Capital245.6 M470.3 M85.6 M
Slightly volatile
Short Term Debt123.5 K130 K11.6 M
Slightly volatile
Common Stock2.9 KK77.2 M
Slightly volatile
Property Plant Equipment1.6 MM1.3 M
Slightly volatile
Capital Lease Obligations1.9 M1.7 M1.7 M
Pretty Stable

Disc Medicine Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income22.4 M21.3 M3.5 M
Slightly volatile
Depreciation And Amortization140.6 K90 K259.6 K
Slightly volatile
Selling General Administrative17.7 M33 M9.8 M
Slightly volatile
Other Operating Expenses56 M104.8 M44 M
Slightly volatile
Research Development55.6 M96.7 M36.9 M
Slightly volatile
Cost Of Revenue85.5 K90 K269.3 K
Slightly volatile
Total Operating Expenses73.3 M129.7 M46.7 M
Slightly volatile
Reconciled Depreciation143.7 K156 K266.4 K
Slightly volatile
Selling And Marketing Expenses17.5 M19.7 M21.4 M
Slightly volatile

Disc Medicine Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation17.7 M16.8 M2.5 M
Slightly volatile
Begin Period Cash Flow378.6 M360.6 M67.8 M
Slightly volatile
Other Cashflows From Financing Activities1.9 MM28.3 M
Pretty Stable
Depreciation111.8 K156 K251.9 K
Slightly volatile
Capital Expenditures530.2 K505 K99.1 K
Slightly volatile
Issuance Of Capital Stock121 M187.3 M54.5 M
Slightly volatile
Total Cash From Financing Activities160.8 M218.3 M77.1 M
Slightly volatile
End Period Cash Flow185 M192.7 M67.2 M
Slightly volatile
Change To Netincome4.2 M8.2 M2.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation3.43.23720.7563
Slightly volatile
Cash Per Share10.8114.535.4626
Slightly volatile
Days Payables Outstanding43.6 K41.5 K11.6 K
Slightly volatile
Income Quality0.690.85890.8118
Pretty Stable
Current Ratio22.2321.17076.2887
Slightly volatile
Capex Per Share0.00440.00460.0126
Slightly volatile
Interest Debt Per Share0.10.1113.0288
Slightly volatile
Debt To Assets0.0590.06040.1312
Slightly volatile
Payables Turnover0.00870.00910.1006
Slightly volatile
Price Earnings To Growth Ratio1.171.110.2581
Slightly volatile
Days Of Payables Outstanding43.6 K41.5 K11.6 K
Slightly volatile
Ebt Per Ebit1.160.961.144
Slightly volatile
Quick Ratio22.2321.17076.2887
Slightly volatile
Net Income Per E B T1.181.151.1434
Slightly volatile
Cash Ratio6.768.25334.332
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.81.00540.9888
Slightly volatile
Debt Ratio0.0590.06040.1312
Slightly volatile

Disc Medicine Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.2 B1.2 B338 M
Slightly volatile
Enterprise Value879.5 M837.6 M197.4 M
Slightly volatile

Disc Fundamental Market Drivers

Cash And Short Term Investments489.9 M

Disc Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Disc Medicine Financial Statements

Disc Medicine investors utilize fundamental indicators, such as revenue or net income, to predict how Disc Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-15.3 M-16.1 M
Cost Of Revenue90 K85.5 K

Pair Trading with Disc Medicine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Disc Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Disc Medicine will appreciate offsetting losses from the drop in the long position's value.

Moving together with Disc Stock

  0.69ME 23Andme HoldingPairCorr

Moving against Disc Stock

  0.84VALN Valneva SE ADRPairCorr
  0.7VIGL Vigil NeurosciencePairCorr
  0.66DMAC DiaMedica TherapeuticsPairCorr
  0.51VERV Verve TherapeuticsPairCorr
  0.5EQ EquilliumPairCorr
The ability to find closely correlated positions to Disc Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Disc Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Disc Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Disc Medicine to buy it.
The correlation of Disc Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Disc Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Disc Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Disc Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Disc Medicine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Disc Medicine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Disc Medicine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Disc Medicine Stock:
Check out the analysis of Disc Medicine Correlation against competitors.
To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Disc Medicine. If investors know Disc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Disc Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.96)
Return On Assets
(0.19)
Return On Equity
(0.28)
The market value of Disc Medicine is measured differently than its book value, which is the value of Disc that is recorded on the company's balance sheet. Investors also form their own opinion of Disc Medicine's value that differs from its market value or its book value, called intrinsic value, which is Disc Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Disc Medicine's market value can be influenced by many factors that don't directly affect Disc Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Disc Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.